Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$156.45 USD

156.45
13,991,025

+5.79 (3.84%)

Updated Aug 25, 2026 04:04 PM ET

After-Market: $156.65 +0.20 (0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (103 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's What Key Metrics Tell Us About Merck (MRK) Q2 Earnings

by Zacks Equity Research

Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

AZN Q2 Earnings Meet Estimates, Sales Beat as Key Drugs Outperform

by Zacks Equity Research

AZN's second-quarter revenues beat on strong drug sales across Oncology and CVRM despite in-line earnings.

Zacks Equity Research

Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?

by Zacks Equity Research

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.

Zacks Equity Research

Merck (MRK) Tops Q2 Earnings Estimates

by Zacks Equity Research

Merck (MRK) delivered earnings and revenue surprises of +5.97% and -0.02%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

S&P 500 & Nasdaq Notch New All-Time Closing Highs

by Mark Vickery

Markets lost a bit of steam mid-session this Monday, but a late surge into the close brought the S&P 500 and the Nasdaq indexes to new record closing highs.

Ahan Chakraborty headshot

Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?

by Ahan Chakraborty

Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.

Kinjel Shah headshot

Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?

by Kinjel Shah

MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth.

Zacks Equity Research

Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues

by Zacks Equity Research

RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.

Ekta Bagri headshot

Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?

by Ekta Bagri

BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.

Sundeep Ganoria headshot

How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?

by Sundeep Ganoria

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.